Publications:

Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.

Cancers

Raivola, Juuli J; Haikarainen, Teemu T; Silvennoinen, Olli O

Publication Date: 2019-12-27

Variant appearance in text: JAK2: I559F

PubMed Link: 31892268

Variant Present in the following documents:

• Main text
• cancers-12-00078.pdf

View BVdb publication page

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.

Frontiers In Oncology

Raivola, Juuli J; Hammarén, Henrik M HM; Virtanen, Anniina T AT; Bulleeraz, Vilasha V; Ward, Alister C AC; Silvennoinen, Olli O

Publication Date: 2018

Variant appearance in text: JAK2: I559F

PubMed Link: 30560087

Variant Present in the following documents:

• Main text
• fonc-08-00560.pdf

View BVdb publication page

Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

The Journal Of Allergy And Clinical Immunology

Hammarén, Henrik M HM; Virtanen, Anniina T AT; Abraham, Bobin George BG; Peussa, Heidi H; Hubbard, Stevan R SR; Silvennoinen, Olli O

Publication Date: 2019-04

Variant appearance in text: JAK2: I559F

PubMed Link: 30092288

Variant Present in the following documents:

• Main text

View BVdb publication page

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Proceedings Of The National Academy Of Sciences Of The United States Of America

Hammarén, Henrik M HM; Ungureanu, Daniela D; Grisouard, Jean J; Skoda, Radek C RC; Hubbard, Stevan R SR; Silvennoinen, Olli O

Publication Date: 2015-04-14

Variant appearance in text: JAK2: I559F

PubMed Link: 25825724

Variant Present in the following documents:

• Main text

View BVdb publication page